5-MEO-DALT

5-MeO-DALT Summary

IUPAC Name: N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-(prop-2-en-1-yl)prop-2-en-1-amine

Molecular Weight: 270.369

Formula: C17H22N2O

InChI: InChI=1S/C17H22N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h4-7,12-13,18H,1-2,8-11H2,3H3

InChI Key: HGRHWEAUHXYNNP-UHFFFAOYSA-N

SMILES: COc1ccc2c(c1)c(CCN(CC=C)CC=C)c[nH]2

Links:

Similar Compounds:

2-ME-DMT
DIPT
MIPT
MPT
MET
DPT
4-ACO-DMT
4-ACO-MET
4-ACO-DET
4-HO-MIPT
4-HO-MET
4-ACO-DPT
4-ACO-MIPT
4-HO-DET
4-HO-MCPT
4-HO-EPT
4-HO-MPT
4-HO-MALT
4-MEO-MIPT
EPT
METHALLYLESCALINE
1P-LSD
MIPLA
1B-LSD
1P-ETH-LAD
1CP-LSD
ALD-52
ETH-LAD

References:

Brandt, SD; Tirunarayanapuram, SS; Freeman, S; Dempster, N; Barker, SA; Daley, PF; Cozzi, NV; Martins, CPB. Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines. J. Labelled Compd. Radiopharm., 1 Nov 2008, 51 (14), 423–429. 169 kB. https://doi.org/10.1002/jlcr.1557

Corkery, JM; Durkin, E; Elliott, S; Scchifano, F; Ghodse, AH. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Prog. Neuro-Psychopharmacol. Biol. Psych., 1 Dec 2012, 39 (1), 259—262. 307 kB. https://doi.org/10.1016/j.pnpbp.2012.05.022

Jovel, A; Felthous, A; Bhattacharyya, A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J. Forensic Sci., 1 May 2014, 59 (3), 844–846. 91 kB. https://doi.org/10.1111/1556-4029.12367

Brandt, SD; Kavanagh, PV; Dowling, G; Talbot, B; Westphal, F; Meyer, MR; Maurer, HH; Halberstadt, AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test. Analysis, 1 Jan 2017, 9 (1), 115-126. 1.3 MB. https://doi.org/10.1002/dta.1974

Arunotayanun, W; Dalley, JW; Huang, X; Setola, V; Treble, R; Iversen, L; Roth, BL; Gibbons, S. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘novel psychoactive drugs’. Bioorg. Med. Chem. Lett., 1 Jun 2013, 23 (11), 3411-3415. 1.1 MB. https://doi.org/10.1016/j.bmcl.2013.03.066 #18

Dinger, J; Woods, C; Brandt, SD; Meyer, MR; Maurer, HH. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol. Lett., , 241, 82-94. 2.6 MB. https://doi.org/10.1016/j.toxlet.2015.11.013

Cozzi, NV; Daley, PF. Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines. Bioorg. Med. Chem. Lett., 1 Feb 2016, 26 (3), 959-964. 513 kB. https://doi.org/10.1016/j.bmcl.2015.12.053

Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #5-MeO-DALT  LC,MS

Brandt, SD; Martins, CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines. Trends Anal. Chem., 1 Sep 2010, 29 (8), 858–869. 446 kB. https://doi.org/10.1016/j.trac.2010.04.008 #40

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. BLOTTER, 1 Mar 2018, 3 (1). 1.2 MB. https://doi.org/10.16889/isomerdesign-5

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. Supplementary Data. BLOTTER, 1 Mar 2018, 3 (1). 5.7 MB. https://doi.org/10.16889/isomerdesign-5-supp

Klein, LM; Cozzi, NV; Daley, PF; Brandt, SD; Halberstadt, AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology, 1 Feb 2018, n/a. 2.9 MB. https://doi.org/10.1016/j.neuropharm.2018.02.028

Caspar, AT; Gaab, JB; Michely, JA; Brandt, SD; Meyer, MR; Maurer, HH. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC–MS, LC–MSn, and LC-HR-MSMS. Drug Test. Analysis, 1 Jan 2018, 10 (1), 184–195. 546 kB. https://doi.org/10.1002/dta.2197

Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b

Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Analysis, 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315

Nichols, DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #18

Taschwer, M; Ebner, E; Schmid, MG. Test purchase of new synthetic tryptamines via the Internet: Identity check by GC-MS and separation by HPLC. J. Appl. Pharm. Sci., 1 Jan 2016, 6 (1), 028–034. 504 kB. https://doi.org/10.7324/JAPS.2016.600105

Nagai, F; Nonaka, R; Kamimura, KSH. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol., 22 Mar 2007, 559 (2), 132–137. 399 kB. https://doi.org/10.1016/j.ejphar.2006.11.075 #5-MeO-DALT

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #5-MeO-DALT

EMCDDA. New drugs in Europe, 2007, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2008. 381 kB. #2

Seto, T; Takahashi, M; Nagashima, M; Suzuki, J; Yasuda, I. The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 75–80. 1.2 MB. #5-MeO-DALT  MS,NMR,UV